{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:48:55Z","timestamp":1775267335789,"version":"3.50.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272956"],"award-info":[{"award-number":["82272956"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12072-024-10755-6","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T07:47:18Z","timestamp":1738741638000},"page":"70-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chinese expert consensus on clinical management of hepatopathy-related thrombocytopenia (2023 edition)"],"prefix":"10.1007","volume":"19","author":[{"given":"Hang","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"issue":"10","key":"10755_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1155\/2014\/532191","volume":"28","author":"VG Gangireddy","year":"2014","unstructured":"Gangireddy VG, Kanneganti PC, Sridhar S, Talla S, Coleman T. Management of thrombocytopenia in advanced liver disease. Can J Gastroenterol Hepatol. 2014;28(10):558\u2013564. https:\/\/doi.org\/10.1155\/2014\/532191","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"5","key":"10755_CR2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.bj.2021.09.001","volume":"45","author":"CE Huang","year":"2022","unstructured":"Huang CE, Chang JJ, Wu YY, et al. Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection. Biomed J. 2022;45(5):788\u2013797. https:\/\/doi.org\/10.1016\/j.bj.2021.09.001","journal-title":"Biomed J"},{"issue":"2","key":"10755_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/jco.21.00608","volume":"40","author":"QJ Li","year":"2022","unstructured":"Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40(2):150\u2013160. https:\/\/doi.org\/10.1200\/jco.21.00608","journal-title":"J Clin Oncol"},{"issue":"6","key":"10755_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/s2468-1253(18)30078-5","volume":"3","author":"M Kudo","year":"2018","unstructured":"Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):424\u2013432. https:\/\/doi.org\/10.1016\/s2468-1253(18)30078-5","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10755_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/liv.13317","volume":"37","author":"M Peck-Radosavljevic","year":"2017","unstructured":"Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017;37(6):778\u2013793. https:\/\/doi.org\/10.1111\/liv.13317","journal-title":"Liver Int"},{"issue":"30","key":"10755_CR6","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.3748\/wjg.v28.i30.4061","volume":"28","author":"P Gallo","year":"2022","unstructured":"Gallo P, Terracciani F, Di Pasquale G, Esposito M, Picardi A, Vespasiani-Gentilucci U. Thrombocytopenia in chronic liver disease: physiopathology and new therapeutic strategies before invasive procedures. World J Gastroenterol. 2022;28(30):4061\u20134074. https:\/\/doi.org\/10.3748\/wjg.v28.i30.4061","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10755_CR7","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1046\/j.1365-2141.2001.02824.x","volume":"113","author":"LE Adinolfi","year":"2001","unstructured":"Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol. 2001;113(3):590\u2013595. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02824.x","journal-title":"Br J Haematol"},{"issue":"1","key":"10755_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2893.2010.01366.x","volume":"18","author":"KS Louie","year":"2011","unstructured":"Louie KS, Micallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. J Viral Hepat. 2011;18(1):1\u20137. https:\/\/doi.org\/10.1111\/j.1365-2893.2010.01366.x","journal-title":"J Viral Hepat"},{"issue":"2","key":"10755_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4240\/wjgs.v15.i2.127","volume":"15","author":"M Biolato","year":"2023","unstructured":"Biolato M, Vitale F, Galasso T, Gasbarrini A, Grieco A. Minimum platelet count threshold before invasive procedures in cirrhosis: evolution of the guidelines. World J Gastrointest Surg. 2023;15(2):127\u2013141. https:\/\/doi.org\/10.4240\/wjgs.v15.i2.127","journal-title":"World J Gastrointest Surg"},{"issue":"3","key":"10755_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/ajh.2830500305","volume":"50","author":"J Pereira","year":"1995","unstructured":"Pereira J, Accatino L, Alfaro J, Brahm J, Hidalgo P, Mezzano D. Platelet autoantibodies in patients with chronic liver disease. Am J Hematol. 1995;50(3):173\u2013178. https:\/\/doi.org\/10.1002\/ajh.2830500305","journal-title":"Am J Hematol"},{"issue":"6","key":"10755_CR11","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1053\/jhep.2003.50209","volume":"37","author":"M Kajihara","year":"2003","unstructured":"Kajihara M, Kato S, Okazaki Y, et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology. 2003;37(6):1267\u20131276. https:\/\/doi.org\/10.1053\/jhep.2003.50209","journal-title":"Hepatology"},{"issue":"4","key":"10755_CR12","first-page":"462","volume":"22","author":"H Xiao","year":"2019","unstructured":"Xiao H, Wang L. Mechanisms of throm bocytopenia in liver cirrhosis. J Pract Hepatol. 2019;22(4):462\u2013465 (in Chinese)","journal-title":"J Pract Hepatol"},{"key":"10755_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/hmer.S74612","volume":"8","author":"O Mitchell","year":"2016","unstructured":"Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39\u201350. https:\/\/doi.org\/10.2147\/hmer.S74612","journal-title":"Hepat Med"},{"issue":"4","key":"10755_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100316","volume":"3","author":"Y Iwakiri","year":"2021","unstructured":"Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy. JHEP Rep. 2021;3(4): 100316. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100316","journal-title":"JHEP Rep"},{"issue":"8","key":"10755_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3760\/cma.j.issn.0253-2727.2020.08.001","volume":"41","author":"Thrombosis and Hemostasis Group, Chinese Society of Hematology, Association CM","year":"2020","unstructured":"Thrombosis and Hemostasis Group, Chinese Society of Hematology, Association CM. Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020). Zhonghua Xue Ye Xue Za Zhi. 2020;41(8):617\u2013623. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2020.08.001","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"10755_CR16","first-page":"42","volume":"36","author":"Chinese Society of Hepatology, Chinese Medical Association","year":"2022","unstructured":"Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of autoimmune hepatitis (2021). J Clin Hepatol. 2022;36(1):42\u201349 (in Chinese)","journal-title":"J Clin Hepatol"},{"issue":"4","key":"10755_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3760\/cma.j.cn501113-20220413-00193","volume":"30","author":"Bureau of Medical Administration, National Health Commission of the People's Republic of China","year":"2022","unstructured":"Bureau of Medical Administration, National Health Commission of the People\u2019s Republic of China. Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition). Zhonghua Gan Zang Bing Za Zhi. 2022;30(4):367\u2013388. https:\/\/doi.org\/10.3760\/cma.j.cn501113-20220413-00193","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"5","key":"10755_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","volume":"14","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, Soff GA. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. Expert Rev Hematol. 2021;14(5):437\u2013448. https:\/\/doi.org\/10.1080\/17474086.2021.1924053","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"10755_CR19","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3760\/cma.j.issn.0253-2727.2022.11.001","volume":"43","author":"Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association","year":"2022","unstructured":"Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Guidelines for the diagnosis and management of aplastic anemia in China. Zhonghua Xue Ye Xue Za Zhi. 2022;43(11):881\u2013888. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2022.11.001","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"8","key":"10755_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3760\/cma.j.issn.0376-2491.2019.08.001","volume":"99","author":"BY Yang","year":"2019","unstructured":"Yang BY. Climical recognition and management of thrombocytopenia in solid tumor. Zhonghua Yi Xue Za Zhi. 2019;99(8):561\u2013565. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2019.08.001","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"1","key":"10755_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17474086.2017.1271319","volume":"10","author":"M Franchini","year":"2017","unstructured":"Franchini M, Veneri D, Lippi G. Thrombocytopenia and infections. Expert Rev Hematol. 2017;10(1):99\u2013106. https:\/\/doi.org\/10.1080\/17474086.2017.1271319","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"10755_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000511759","volume":"144","author":"A Klein","year":"2021","unstructured":"Klein A, Molad Y. Hematological manifestations among patients with rheumatic diseases. Acta Haematol. 2021;144(4):403\u2013412. https:\/\/doi.org\/10.1159\/000511759","journal-title":"Acta Haematol"},{"issue":"12","key":"10755_CR23","first-page":"1166","volume":"38","author":"LP Li","year":"2022","unstructured":"Li LP, Ying H. Etiology and differential diagnosis of thrombocytopenia in pregnancy. Zhongguo shiyong fuke yu chanke zazhi. 2022;38(12):1166\u20131170 (in Chinese)","journal-title":"Zhongguo shiyong fuke yu chanke zazhi."},{"issue":"4","key":"10755_CR24","first-page":"55","volume":"20","author":"YY He","year":"2018","unstructured":"He YY. Application value of etiological analysis of hemolytic diseases in the diagnosis and differential diagnosis of hereditary hemolytic anaemia. Mod Med J China. 2018;20(4):55\u201357 (in Chinese)","journal-title":"Mod Med J China."},{"issue":"1","key":"10755_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12185-020-02992-w","volume":"113","author":"T Ikezoe","year":"2021","unstructured":"Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol. 2021;113(1):34\u201344. https:\/\/doi.org\/10.1007\/s12185-020-02992-w","journal-title":"Int J Hematol"},{"issue":"1","key":"10755_CR26","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1515\/cclm-2020-0128","volume":"59","author":"A Asma","year":"2020","unstructured":"Asma A, Anissa S, Touhami K. Aggregation kinetic and temperature optimum of an EDTA-dependent pseudothrombocytopenia. Clin Chem Lab Med. 2020;59(1):e31\u2013e33. https:\/\/doi.org\/10.1515\/cclm-2020-0128","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"10755_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 50) to evaluate the severity of adverse events of anticancer therapies (CTCAE versi\u00f3n 5.0. Evaluaci\u00f3n de la gravedad de los eventos adversos dermatol\u00f3gicos de las terapias antineopl\u00e1sicas). Actas Dermosifiliogr (Engl Ed). 2021;112(1):90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"6","key":"10755_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13508","volume":"51","author":"D Alvaro","year":"2021","unstructured":"Alvaro D, Caporaso N, Giannini EG, et al. Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia. Eur J Clin Invest. 2021;51(6): e13508. https:\/\/doi.org\/10.1111\/eci.13508","journal-title":"Eur J Clin Invest"},{"issue":"01","key":"10755_CR29","first-page":"1","volume":"30","author":"Writing Group of the Xiangya Expert Consensus on Liver Needle Biopsy","year":"2021","unstructured":"Writing Group of the Xiangya Expert Consensus on Liver Needle Biopsy. Xiangya expert consensus on liver needle biopsy. Chin J Gen Surg. 2021;30(01):1\u20138 (in Chinese)","journal-title":"Chin J Gen Surg"},{"issue":"7","key":"10755_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3760\/cma.j.cn112137-20210425-00991","volume":"60","author":"Clinical Guidelines Committee of Chinese Interventionalists College","year":"2021","unstructured":"Clinical Guidelines Committee of Chinese Interventionalists College. Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma. Zhonghua Nei Ke Za Zhi. 2021;60(7):599\u2013614. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20210425-00991","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"5","key":"10755_CR31","doi-asserted-by":"publisher","first-page":"e658","DOI":"10.3747\/co.26.5423","volume":"26","author":"GZ Wang","year":"2019","unstructured":"Wang GZ, He XH, Wang Y, et al. Clinical practice guideline for image-guided multimode tumor ablation therapy in hepatic malignant tumours. Curr Oncol. 2019;26(5):e658\u2013e664. https:\/\/doi.org\/10.3747\/co.26.5423","journal-title":"Curr Oncol"},{"issue":"7","key":"10755_CR32","first-page":"754","volume":"20","author":"Chinese Society of Liver Cancer China Anti-Cancer Association","year":"2021","unstructured":"Chinese Society of Liver Cancer China Anti-Cancer Association. Chinese expert consensus on hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Chin J Dig Surg. 2021;20(7):754\u2013759 (in Chinese)","journal-title":"Chin J Dig Surg"},{"issue":"7","key":"10755_CR33","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1136\/gutjnl-2019-320221","volume":"69","author":"D Tripathi","year":"2020","unstructured":"Tripathi D, Stanley AJ, Hayes PC, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut. 2020;69(7):1173\u20131192. https:\/\/doi.org\/10.1136\/gutjnl-2019-320221","journal-title":"Gut"},{"issue":"1","key":"10755_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3760\/cma.j.issn.1007-3418.2019.01.006","volume":"27","author":"Liver Failure and Artificial Liver Group, Society of Infectious Diseases, Chinese Medical Association, Severe Liver Disease and Artificial Liver Group, Society of Hepatology, Association CM","year":"2019","unstructured":"Liver Failure and Artificial Liver Group, Society of Infectious Diseases, Chinese Medical Association, Severe Liver Disease and Artificial Liver Group, Society of Hepatology, Association CM. Guideline for diagnosis and treatment of liver failure. Zhonghua Gan Zang Bing Za Zhi. 2019;27(1):18\u201326. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2019.01.006","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"7","key":"10755_CR35","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3760\/cma.j.cn501113-20210604-00261","volume":"29","author":"The Chinese Chapter of the International Hepato-Pancreato-Biliary Association, Group of Liver Surgery, Surgical Society of Chinese Medical Association, Expert Committee on Liver Cancer, Chinese Society of Clinical Oncology","year":"2021","unstructured":"The Chinese Chapter of the International Hepato-Pancreato-Biliary Association, Group of Liver Surgery, Surgical Society of Chinese Medical Association, Expert Committee on Liver Cancer, Chinese Society of Clinical Oncology. Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma (2021 version). Zhonghua Gan Zang Bing Za Zhi. 2021;29(7):636\u2013647. https:\/\/doi.org\/10.3760\/cma.j.cn501113-20210604-00261","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"28","key":"10755_CR36","first-page":"2185","volume":"101","author":"Chinese Society of Liver Cancer, China Medical and Doctor Association","year":"2021","unstructured":"Chinese Society of Liver Cancer, China Medical and Doctor Association. Chinese expert consensus on the clinical application of molecular targeted drugs for hepatocellular carcinoma (2021 edition). Natl Med J China. 2021;101(28):2185\u20132194 (in Chinese)","journal-title":"Natl Med J China"},{"issue":"7","key":"10755_CR37","first-page":"648","volume":"29","author":"Nuclear Medicine Committee, Oncology CSoC","year":"2021","unstructured":"Nuclear Medicine Committee, Oncology CSoC. Chinese expert consensus on selective internal radiation therapy with yttrium-90 for primary and metastatic hepatocellular carcinoma. Chin J Hepatol. 2021;29(7):648\u2013658 (in Chinese)","journal-title":"Chin J Hepatol"},{"issue":"6","key":"10755_CR38","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","volume":"107","author":"DJ Kuter","year":"2022","unstructured":"Kuter DJ. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica. 2022;107(6):1243\u20131263. https:\/\/doi.org\/10.3324\/haematol.2021.279512","journal-title":"Haematologica"},{"issue":"12","key":"10755_CR39","first-page":"1129","volume":"25","author":"Anti-Lymphoma Alliance in CSCO, Anti-Leukemia Alliance in CSCO, ASMC Group in CSCO","year":"2020","unstructured":"Anti-Lymphoma Alliance in CSCO, Anti-Leukemia Alliance in CSCO, ASMC Group in CSCO. Chinese expert consensus on the clinical application of recombinant human interleukin-11 for the treatment of thrombocytopenia (2021 edition). Chin Clin Oncol. 2020;25(12):1129\u20131137 (in Chinese)","journal-title":"Chin Clin Oncol"},{"key":"10755_CR40","doi-asserted-by":"publisher","first-page":"5421632","DOI":"10.1155\/2020\/5421632","volume":"2020","author":"F Poordad","year":"2020","unstructured":"Poordad F, Terrault NA, Alkhouri N, Tian W, Allen LF, Rabinovitz M. Avatrombopag, an alternate treatment option to reduce platelet transfusions in patients with thrombocytopenia and chronic liver disease-integrated analyses of 2 phase 3 studies. Int J Hepatol. 2020;2020:5421632. https:\/\/doi.org\/10.1155\/2020\/5421632","journal-title":"Int J Hepatol"},{"key":"10755_CR41","doi-asserted-by":"publisher","first-page":"9138195","DOI":"10.1155\/2022\/9138195","volume":"2022","author":"A Huang","year":"2022","unstructured":"Huang A, Chen JF, Wu JZ, et al. Effectiveness and safety of avatrombopag in liver cancer patients with severe thrombocytopenia: real-world data and challenges. J Oncol. 2022;2022:9138195. https:\/\/doi.org\/10.1155\/2022\/9138195","journal-title":"J Oncol"},{"issue":"12","key":"10755_CR42","first-page":"1086","volume":"41","author":"RX Li","year":"2021","unstructured":"Li RX, Yang H, Song YH, et al. Report of two cases of avatrombopag combined with intensified immunosuppressive in treatment of severe hepatitis-associated aplastic anaemia. Chin J Pract Internal Med. 2021;41(12):1086\u20131088 (in Chinese)","journal-title":"Chin J Pract Internal Med"},{"issue":"10","key":"10755_CR43","first-page":"618","volume":"30","author":"RX Li","year":"2021","unstructured":"Li RX, Liu ZY, Zhou JT, et al. Avatrombopag in treatment of lenvatinib-related severe aplastic anemia: report of one case and review of literature. J Leukemia Lymphom. 2021;30(10):618\u2013620 (in Chinese)","journal-title":"J Leukemia Lymphom"},{"issue":"6","key":"10755_CR44","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cgh.2018.11.047","volume":"17","author":"H Hidaka","year":"2019","unstructured":"Hidaka H, Kurosaki M, Tanaka H, et al. Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures. Clin Gastroenterol Hepatol. 2019;17(6):1192\u20131200. https:\/\/doi.org\/10.1016\/j.cgh.2018.11.047","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10755_CR45","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/hep.30561","volume":"70","author":"M Peck-Radosavljevic","year":"2019","unstructured":"Peck-Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology. 2019;70(4):1336\u20131348. https:\/\/doi.org\/10.1002\/hep.30561","journal-title":"Hepatology"},{"issue":"1","key":"10755_CR46","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12072-022-10421-9","volume":"17","author":"Z Ding","year":"2023","unstructured":"Ding Z, Wu H, Zeng Y, et al. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures. Hepatol Int. 2023;17(1):180\u2013189. https:\/\/doi.org\/10.1007\/s12072-022-10421-9","journal-title":"Hepatol Int"},{"issue":"8","key":"10755_CR47","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1056\/NEJMoa1110709","volume":"367","author":"NH Afdhal","year":"2012","unstructured":"Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716\u2013724. https:\/\/doi.org\/10.1056\/NEJMoa1110709","journal-title":"N Engl J Med"},{"issue":"2","key":"10755_CR48","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1053\/j.gastro.2013.10.012","volume":"146","author":"NH Afdhal","year":"2014","unstructured":"Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014;146(2):442\u201352.e1. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.012","journal-title":"Gastroenterology"},{"issue":"6","key":"10755_CR49","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.21037\/apm-21-1067","volume":"10","author":"P Zhang","year":"2021","unstructured":"Zhang P, Miao W. Eltrombopag-induced liver dysfunction during the treatment of immune thrombocytopenia and its risk factors. Ann Palliat Med. 2021;10(6):6419\u20136424. https:\/\/doi.org\/10.21037\/apm-21-1067","journal-title":"Ann Palliat Med"},{"issue":"2","key":"10755_CR50","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1440-1746.2012.07246.x","volume":"28","author":"MM Moussa","year":"2013","unstructured":"Moussa MM, Mowafy N. Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis. J Gastroenterol Hepatol. 2013;28(2):335\u2013341. https:\/\/doi.org\/10.1111\/j.1440-1746.2012.07246.x","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10755_CR51","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/jvh.13655","volume":"29","author":"R Feng","year":"2022","unstructured":"Feng R, Liu Y, Zhu XL, et al. Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B-related cirrhosis: Multicentre real-world observational study. J Viral Hepat. 2022;29(5):306\u2013316. https:\/\/doi.org\/10.1111\/jvh.13655","journal-title":"J Viral Hepat"},{"issue":"11","key":"10755_CR52","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.4240\/wjgs.v14.i11.1260","volume":"14","author":"JN Ding","year":"2022","unstructured":"Ding JN, Feng TT, Sun W, Cai XY, Zhang Y, Zhao WF. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: a retrospective study. World J Gastrointest Surg. 2022;14(11):1260\u20131271. https:\/\/doi.org\/10.4240\/wjgs.v14.i11.1260","journal-title":"World J Gastrointest Surg"},{"issue":"34","key":"10755_CR53","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.11569\/wcjd.v24.i34.4608","volume":"24","author":"BW Liu","year":"2016","unstructured":"Liu BW, Xiang HL, Liang J, Han T. Comparison of efficacy of recombinant human interleukin-11 and recombinant human thrombopoietin in treating thrombocytopenia with hypersplenism in cirrhotic patients. World Chin J Digestol. 2016;24(34):4608\u20134614 (in Chinese)","journal-title":"World Chin J Digestol"},{"issue":"8","key":"10755_CR54","first-page":"1878","volume":"37","author":"L Liu","year":"2021","unstructured":"Liu L, Liu Y, Gao FY, Wang XB. Clinical features of chronic liver disease with autoimmune blood disorders and the clinical effect of glucocorticoid therapy. J Clin Hepatol. 2021;37(8):1878\u20131882 (in Chinese)","journal-title":"J Clin Hepatol"},{"issue":"4","key":"10755_CR55","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1007\/s12325-021-01652-7","volume":"38","author":"Y Wu","year":"2021","unstructured":"Wu Y, Li H, Zhang T, et al. Splanchnic vein thrombosis in liver cirrhosis after splenectomy or splenic artery embolization: a systematic review and meta-analysis. Adv Ther. 2021;38(4):1904\u20131930. https:\/\/doi.org\/10.1007\/s12325-021-01652-7","journal-title":"Adv Ther"},{"issue":"1","key":"10755_CR56","first-page":"82","volume":"23","author":"P Zhao","year":"2020","unstructured":"Zhao P, Li T, Xiw JL, Zheng B. Value of early anticoagulant intervention in cirrhotic patients with portal hypertension after transjugular intrahepatic portosystemic stent shunt combined with PSE. J Pract Hepatol. 2020;23(1):82\u201385 (in Chinese)","journal-title":"J Pract Hepatol"},{"issue":"3","key":"10755_CR57","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/bjs.7367","volume":"98","author":"K Feng","year":"2011","unstructured":"Feng K, Ma K, Liu Q, Wu Q, Dong J, Bie P. Randomized clinical trial of splenic radiofrequency ablation versus splenectomy for severe hypersplenism. Br J Surg. 2011;98(3):354\u2013361. https:\/\/doi.org\/10.1002\/bjs.7367","journal-title":"Br J Surg"},{"issue":"2","key":"10755_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2739\/kurumemedj.ms62010","volume":"60","author":"T Ogata","year":"2013","unstructured":"Ogata T, Okuda K, Sato T, et al. Long-term outcome of splenectomy in advanced cirrhotic patients with hepatocellular carcinoma and thrombocytopenia. Kurume Med J. 2013;60(2):37\u201345. https:\/\/doi.org\/10.2739\/kurumemedj.ms62010","journal-title":"Kurume Med J"},{"issue":"8","key":"10755_CR59","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1080\/09537104.2019.1704715","volume":"31","author":"H Zhang","year":"2020","unstructured":"Zhang H, Zhang S, Zhang J, et al. Improvement of human platelet aggregation post-splenectomy with paraesophagogastric devascularization in chronic hepatitis B patients with cirrhotic hypersplenism. Platelets. 2020;31(8):1019\u20131027. https:\/\/doi.org\/10.1080\/09537104.2019.1704715","journal-title":"Platelets"},{"issue":"5","key":"10755_CR60","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1080\/13645706.2021.1933535","volume":"31","author":"Y Huang","year":"2022","unstructured":"Huang Y, Ren D, Gao F, et al. An updated meta-analysis of partial splenic embolization versus splenectomy in the treatment of hypersplenism due to cirrhosis. Minim Invasive Ther Allied Technol. 2022;31(5):664\u2013675. https:\/\/doi.org\/10.1080\/13645706.2021.1933535","journal-title":"Minim Invasive Ther Allied Technol"},{"issue":"8","key":"10755_CR61","doi-asserted-by":"publisher","first-page":"641","DOI":"10.21037\/atm-20-6748","volume":"9","author":"XB Shi","year":"2021","unstructured":"Shi XB, Feng JK, Wang JH, Jiang XQ. Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta-analysis. Ann Transl Med. 2021;9(8):641. https:\/\/doi.org\/10.21037\/atm-20-6748","journal-title":"Ann Transl Med"},{"key":"10755_CR62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12893-015-0077-2","volume":"15","author":"H Chu","year":"2015","unstructured":"Chu H, Han W, Wang L, et al. Long-term efficacy of subtotal splenectomy due to portal hypertension in cirrhotic patients. BMC Surg. 2015;15:89. https:\/\/doi.org\/10.1186\/s12893-015-0077-2","journal-title":"BMC Surg"},{"issue":"4","key":"10755_CR63","first-page":"7534","volume":"9","author":"X Liu","year":"2016","unstructured":"Liu X, Qi X, Li H, Chen J, Guo X. Prevalence of portal or splenic vein thrombosis in cirrhotic patients after splenectomy: a systematic review and meta-analysis of observational studies. Int J Clin Exp Med. 2016;9(4):7534\u20137547","journal-title":"Int J Clin Exp Med"},{"issue":"3","key":"10755_CR64","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/liv.12038","volume":"33","author":"A Tripodi","year":"2013","unstructured":"Tripodi A, Primignani M, Chantarangkul V, et al. Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. Liver Int. 2013;33(3):362\u2013367. https:\/\/doi.org\/10.1111\/liv.12038","journal-title":"Liver Int"},{"issue":"04","key":"10755_CR65","first-page":"328","volume":"19","author":"SY Wang","year":"2017","unstructured":"Wang SY, Zhou WH, Li XY, Zhang YL, Niu GT, Feng YQ. Analysis of platelet transfusion in liver disease patient. J Clin Transfus Lab Med. 2017;19(04):328\u2013331 (in Chinese)","journal-title":"J Clin Transfus Lab Med"},{"issue":"9","key":"10755_CR66","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/hepr.13530","volume":"50","author":"Y Furuichi","year":"2020","unstructured":"Furuichi Y, Takeuchi H, Yoshimasu Y, Kasai Y, Abe M, Itoi T. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching. Hepatol Res. 2020;50(9):1062\u20131070. https:\/\/doi.org\/10.1111\/hepr.13530","journal-title":"Hepatol Res"},{"issue":"04","key":"10755_CR67","first-page":"440","volume":"31","author":"LL Wen","year":"2018","unstructured":"Wen LL, Yu ZL, Liang HL, Ma CH, Guo YJ. Main recommendations of the British guideline of platelet transfusion application and their Implications. Chin J Blood Transfus. 2018;31(04):440\u2013444 (in Chinese)","journal-title":"Chin J Blood Transfus"},{"key":"10755_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153700","volume":"91","author":"H Zhu","year":"2021","unstructured":"Zhu H, Wang SY, Zhu JH, et al. Efficacy and safety of transcatheter arterial chemoembolization combined with ginsenosides in hepatocellular carcinoma treatment. Phytomedicine. 2021;91: 153700. https:\/\/doi.org\/10.1016\/j.phymed.2021.153700","journal-title":"Phytomedicine"},{"issue":"8","key":"10755_CR69","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1111\/liv.14121","volume":"39","author":"C Noronha Ferreira","year":"2019","unstructured":"Noronha Ferreira C, Marinho RT, Cortez-Pinto H, et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: a prospective study. Liver Int. 2019;39(8):1459\u20131467. https:\/\/doi.org\/10.1111\/liv.14121","journal-title":"Liver Int"},{"issue":"1","key":"10755_CR70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejim.2014.12.002","volume":"26","author":"X Qi","year":"2015","unstructured":"Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26(1):23\u201329. https:\/\/doi.org\/10.1016\/j.ejim.2014.12.002","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10755_CR71","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","volume":"153","author":"L Loffredo","year":"2017","unstructured":"Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology. 2017;153(2):480-487.e1. https:\/\/doi.org\/10.1053\/j.gastro.2017.04.042","journal-title":"Gastroenterology"},{"issue":"9","key":"10755_CR72","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000228","volume":"11","author":"T Zhou","year":"2020","unstructured":"Zhou T, Sun X, Zhou T, et al. Efficacy and safety of nadroparin calcium-warfarin sequential anticoagulation in portal vein thrombosis in cirrhotic patients: a randomized controlled trial. Clin Transl Gastroenterol. 2020;11(9): e00228. https:\/\/doi.org\/10.14309\/ctg.0000000000000228","journal-title":"Clin Transl Gastroenterol"},{"issue":"4","key":"10755_CR73","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/1751-2980.12970","volume":"22","author":"Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association","year":"2021","unstructured":"Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis. J Dig Dis. 2021;22(4):176\u2013186. https:\/\/doi.org\/10.1111\/1751-2980.12970","journal-title":"J Dig Dis"},{"issue":"1","key":"10755_CR74","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1378\/chest.09-3081","volume":"139","author":"H Decousus","year":"2011","unstructured":"Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011;139(1):69\u201379. https:\/\/doi.org\/10.1378\/chest.09-3081","journal-title":"Chest"},{"key":"10755_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100054","volume":"4","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhai Z, Li W, et al. Validation of the IMPROVE bleeding risk score in Chinese medical patients during hospitalization: Findings from the dissolve-2 study. Lancet Reg Health West Pac. 2020;4: 100054. https:\/\/doi.org\/10.1016\/j.lanwpc.2020.100054","journal-title":"Lancet Reg Health West Pac"},{"issue":"11","key":"10755_CR76","doi-asserted-by":"publisher","first-page":"E468","DOI":"10.1002\/ajh.24526","volume":"91","author":"N Khanal","year":"2016","unstructured":"Khanal N, Bociek RG, Chen B, et al. Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia. Am J Hematol. 2016;91(11):E468-e472. https:\/\/doi.org\/10.1002\/ajh.24526","journal-title":"Am J Hematol"},{"issue":"8","key":"10755_CR77","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000750","volume":"6","author":"A Falanga","year":"2022","unstructured":"Falanga A, Leader A, Ambaglio C, et al. EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. Hemasphere. 2022;6(8): e750. https:\/\/doi.org\/10.1097\/hs9.0000000000000750","journal-title":"Hemasphere"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10755-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T12:45:13Z","timestamp":1740228313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10755-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10755"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10755-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"3 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hang Yu, Hongli Yu, Yao Sun, and Fu-Sheng Wang declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}